"If you had the power to stop a disease before it started, you would, wouldn’t you?" Cynthia Miller, MD, MPH, CPH, FACP, VP, Medical Director and advocate for preventive care services, speaks about newfound research on lipid management medications on MedCity News. With support from healthcare providers, doctors, pharmaceutical companies, and EHR vendors, we could be on the brink of decreasing the development of and mortality from cardiovascular disease. https://lnkd.in/gZURVVUg
Precision AQ’s Post
More Relevant Posts
-
CARDIOVASCULAR. Comparison of the use of blood pressure telemonitoring versus standard medical care in the achievement of short-term therapeutic goals. Dr. David. #director #gerente #pharma #bigpharma #farma #farmacéutica #farmaceutica #industriafarmacéutica #industriafarmaceutica #cardiovascular #hipertensión
To view or add a comment, sign in
-
This Challenge aims to uncover new approaches to enhancing adherence to antiseizure medications (ASM) in epilepsy patients. Do you have innovative ideas to improve treatment adherence? Unleash your creativity and make a meaningful impact at https://bit.ly/4eVVX2A Angelini Pharma #EpilepsyTreatment #HealthcareInnovation
To view or add a comment, sign in
-
#BREAKING Otsuka America Pharmaceutical, Inc., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://lnkd.in/ergnm-MS #DefyLimitation
To view or add a comment, sign in
-
🌟 Associate Director Customer Strategy | 3x President’s Club Winner | Sales Leader & Mentor | Rare Disease Specialist | LTC Expert | Patient-Centric Advocate 🏥💼 #SalesLeadership #PatientCentricity
#BREAKING Otsuka Pharmaceutical Co., Ltd., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://lnkd.in/eaFszcZg #DefyLimitation
#MyOtsuka - Rejoyn Receives FDA Clearance
To view or add a comment, sign in
-
Associate Director, Northeast & Tristate Regional Patient Lead, Otsuka Patient Experience & Support at Otsuka Pharmaceutical Companies (U.S.)
#BREAKING Otsuka Pharmaceutical Co., Ltd., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://lnkd.in/edivu-mK #DefyLimitation
#MyOtsuka - Rejoyn Receives FDA Clearance
To view or add a comment, sign in
-
Associate Director, Clinical Operations at Otsuka Pharmaceutical Development & Commercialization, Inc.
#BREAKING Otsuka Pharmaceutical Co., Ltd., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://lnkd.in/gQiufZxP #DefyLimitation
#MyOtsuka - Rejoyn Receives FDA Clearance
To view or add a comment, sign in
-
#BREAKING Otsuka Pharmaceutical Co., Ltd., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://lnkd.in/exsC4r-i #DefyLimitation
#MyOtsuka - Rejoyn Receives FDA Clearance
To view or add a comment, sign in
-
#BREAKING Otsuka Pharmaceutical Co., Ltd., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://bit.ly/3PMb6Zb #DefyLimitation
To view or add a comment, sign in